SE0000540D0 - New compounds - Google Patents

New compounds

Info

Publication number
SE0000540D0
SE0000540D0 SE0000540A SE0000540A SE0000540D0 SE 0000540 D0 SE0000540 D0 SE 0000540D0 SE 0000540 A SE0000540 A SE 0000540A SE 0000540 A SE0000540 A SE 0000540A SE 0000540 D0 SE0000540 D0 SE 0000540D0
Authority
SE
Sweden
Prior art keywords
new compounds
compounds
new
formula
Prior art date
Application number
SE0000540A
Other languages
English (en)
Swedish (sv)
Inventor
Eifion Phillips
Richard Schmiesing
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0000540A priority Critical patent/SE0000540D0/xx
Publication of SE0000540D0 publication Critical patent/SE0000540D0/xx
Priority to ARP010100628A priority patent/AR029798A1/es
Priority to TR2004/00072T priority patent/TR200400072T4/xx
Priority to IL15054401A priority patent/IL150544A0/xx
Priority to PT01904770T priority patent/PT1259508E/pt
Priority to EP01904770A priority patent/EP1259508B1/en
Priority to PL357565A priority patent/PL202044B1/pl
Priority to SI200130060T priority patent/SI1259508T1/xx
Priority to AU32594/01A priority patent/AU782693B2/en
Priority to MXPA02007543A priority patent/MXPA02007543A/es
Priority to SK1179-2002A priority patent/SK11792002A3/sk
Priority to UA2002075475A priority patent/UA73540C2/uk
Priority to BR0108456-9A priority patent/BR0108456A/pt
Priority to EEP200200459A priority patent/EE05149B1/xx
Priority to RU2002118302/04A priority patent/RU2263114C2/ru
Priority to CA002397233A priority patent/CA2397233A1/en
Priority to DE60100996T priority patent/DE60100996T2/de
Priority to NZ520094A priority patent/NZ520094A/en
Priority to JP2001560205A priority patent/JP4084570B2/ja
Priority to KR1020027010731A priority patent/KR100769394B1/ko
Priority to AT01904770T priority patent/ATE252099T1/de
Priority to DK01904770T priority patent/DK1259508T3/da
Priority to PCT/SE2001/000329 priority patent/WO2001060821A1/en
Priority to CZ20022787A priority patent/CZ20022787A3/cs
Priority to ES01904770T priority patent/ES2208556T3/es
Priority to HU0301069A priority patent/HUP0301069A3/hu
Priority to CNB018049362A priority patent/CN100345847C/zh
Priority to MYPI20010711A priority patent/MY123580A/en
Priority to CO01012482A priority patent/CO5280046A1/es
Priority to US10/123,856 priority patent/US7001914B2/en
Priority to ZA200205479A priority patent/ZA200205479B/xx
Priority to BG106977A priority patent/BG106977A/bg
Priority to IS6492A priority patent/IS6492A/is
Priority to NO20023917A priority patent/NO20023917L/no
Priority to HK03102250A priority patent/HK1050007A1/xx
Priority to US11/325,787 priority patent/US7214688B2/en
Priority to US11/680,930 priority patent/US7491734B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
SE0000540A 2000-02-18 2000-02-18 New compounds SE0000540D0 (sv)

Priority Applications (37)

Application Number Priority Date Filing Date Title
SE0000540A SE0000540D0 (sv) 2000-02-18 2000-02-18 New compounds
ARP010100628A AR029798A1 (es) 2000-02-18 2001-02-12 Biarilcarboxamidas, su uso en la manufactura de medicamentos, proceso para la preparacion de estos compuestos, e intermediarios utiles en ese proceso
CNB018049362A CN100345847C (zh) 2000-02-18 2001-02-15 新的联芳基甲酰胺
DE60100996T DE60100996T2 (de) 2000-02-18 2001-02-15 Biarylcarboxamide
KR1020027010731A KR100769394B1 (ko) 2000-02-18 2001-02-15 신규 비아릴카르복스아미드
PT01904770T PT1259508E (pt) 2000-02-18 2001-02-15 Novos biarilcarboxamidas
EP01904770A EP1259508B1 (en) 2000-02-18 2001-02-15 Novel biarylcarboxamides
PL357565A PL202044B1 (pl) 2000-02-18 2001-02-15 Nowe biarylokarboksyamidy, ich zastosowanie, sposób wytwarzania biarylokarboksyamidów i związki pośrednie
SI200130060T SI1259508T1 (en) 2000-02-18 2001-02-15 Novel biarylcarboxamides
AU32594/01A AU782693B2 (en) 2000-02-18 2001-02-15 Novel biarylcarboxamides
MXPA02007543A MXPA02007543A (es) 2000-02-18 2001-02-15 Biarilcarboxamidas novedosas.
SK1179-2002A SK11792002A3 (sk) 2000-02-18 2001-02-15 Biarylkarboxamidy, spôsob ich prípravy a ich použitie
UA2002075475A UA73540C2 (en) 2000-02-18 2001-02-15 Diarylcarboxamides
BR0108456-9A BR0108456A (pt) 2000-02-18 2001-02-15 Composto, uso de um composto, métodos de tratamento ou de profilaxia de distúrbios psicóticos ou distúrbios de deterioração intelectual e de doenças humanas, e ,processo para preparação de um composto
EEP200200459A EE05149B1 (et) 2000-02-18 2001-02-15 Biarlkarboksamiidid, meetod nende valmistamiseks, neid sisaldav ravimkoostis ning nende kasutamine ravis
RU2002118302/04A RU2263114C2 (ru) 2000-02-18 2001-02-15 Соединения, лекарственные средства, способы лечения, способ получения соединений
CA002397233A CA2397233A1 (en) 2000-02-18 2001-02-15 Biarylcarboxamides
TR2004/00072T TR200400072T4 (tr) 2000-02-18 2001-02-15 Novel Biarylcarboxamides Biarylcarboxamide Nouveaux Biarylcarboxamides
NZ520094A NZ520094A (en) 2000-02-18 2001-02-15 Novel biarylcarboxamides
JP2001560205A JP4084570B2 (ja) 2000-02-18 2001-02-15 新規なビアリールカルボキサミド
IL15054401A IL150544A0 (en) 2000-02-18 2001-02-15 Novel biarylcarboxamides
AT01904770T ATE252099T1 (de) 2000-02-18 2001-02-15 Biarylcarboxamide
DK01904770T DK1259508T3 (da) 2000-02-18 2001-02-15 Hidtil ukendte biarylcarboxamider
PCT/SE2001/000329 WO2001060821A1 (en) 2000-02-18 2001-02-15 Novel biarylcarboxamides
CZ20022787A CZ20022787A3 (cs) 2000-02-18 2001-02-15 Nové biarylkarboxamidy
ES01904770T ES2208556T3 (es) 2000-02-18 2001-02-15 Nuevas biarilcarboxamidas.
HU0301069A HUP0301069A3 (en) 2000-02-18 2001-02-15 Novel biarylcarboxamides, process for their preparation, pharmaceutical compositions containing them and their use
CO01012482A CO5280046A1 (es) 2000-02-18 2001-02-16 Agonistas alfa 7 y sus composiciones farmaceuticas
MYPI20010711A MY123580A (en) 2000-02-18 2001-02-16 Novel biarylcarboxamides
US10/123,856 US7001914B2 (en) 2000-02-18 2002-04-15 Compounds
ZA200205479A ZA200205479B (en) 2000-02-18 2002-07-09 Novel biarylcarboxamides.
BG106977A BG106977A (bg) 2000-02-18 2002-08-02 Нови биарилкарбоксамиди
IS6492A IS6492A (is) 2000-02-18 2002-08-08 Ný bíarýlkarboxamíð
NO20023917A NO20023917L (no) 2000-02-18 2002-08-16 Nye biarylkarboksamider
HK03102250A HK1050007A1 (en) 2000-02-18 2003-03-28 Novel biarylcarboxamides
US11/325,787 US7214688B2 (en) 2000-02-18 2006-01-05 Compounds
US11/680,930 US7491734B2 (en) 2000-02-18 2007-03-01 2-(pyridine-4-yl)-N-(quinuclidin-2-yl)thiazole-4-carboxide nicotinic acetylcholine receptor ligands

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0000540A SE0000540D0 (sv) 2000-02-18 2000-02-18 New compounds

Publications (1)

Publication Number Publication Date
SE0000540D0 true SE0000540D0 (sv) 2000-02-18

Family

ID=20278508

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0000540A SE0000540D0 (sv) 2000-02-18 2000-02-18 New compounds

Country Status (34)

Country Link
US (3) US7001914B2 (sk)
EP (1) EP1259508B1 (sk)
JP (1) JP4084570B2 (sk)
KR (1) KR100769394B1 (sk)
CN (1) CN100345847C (sk)
AR (1) AR029798A1 (sk)
AT (1) ATE252099T1 (sk)
AU (1) AU782693B2 (sk)
BG (1) BG106977A (sk)
BR (1) BR0108456A (sk)
CA (1) CA2397233A1 (sk)
CO (1) CO5280046A1 (sk)
CZ (1) CZ20022787A3 (sk)
DE (1) DE60100996T2 (sk)
DK (1) DK1259508T3 (sk)
EE (1) EE05149B1 (sk)
ES (1) ES2208556T3 (sk)
HK (1) HK1050007A1 (sk)
HU (1) HUP0301069A3 (sk)
IL (1) IL150544A0 (sk)
IS (1) IS6492A (sk)
MX (1) MXPA02007543A (sk)
MY (1) MY123580A (sk)
NO (1) NO20023917L (sk)
NZ (1) NZ520094A (sk)
PL (1) PL202044B1 (sk)
PT (1) PT1259508E (sk)
RU (1) RU2263114C2 (sk)
SE (1) SE0000540D0 (sk)
SK (1) SK11792002A3 (sk)
TR (1) TR200400072T4 (sk)
UA (1) UA73540C2 (sk)
WO (1) WO2001060821A1 (sk)
ZA (1) ZA200205479B (sk)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0000540D0 (sv) * 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
US6492385B2 (en) 2000-08-18 2002-12-10 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
AU2001284645A1 (en) * 2000-08-18 2002-03-04 Pharmacia And Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
WO2002016357A2 (en) * 2000-08-18 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
EP1381603A2 (en) 2000-08-18 2004-01-21 PHARMACIA & UPJOHN COMPANY Quinuclidine-substituedaryl moieties for treatment of disease ( nicotinic acetylcholine receptor ligands )
WO2002017358A2 (en) * 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists)
WO2002016355A2 (en) * 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic) acetylcholine receptor ligands
AU2001284646A1 (en) * 2000-08-21 2002-03-04 Pharmacia And Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
PE20021019A1 (es) * 2001-04-19 2002-11-13 Upjohn Co Grupos azabiciclicos sustituidos
AR036040A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
AR036041A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen
WO2003018585A1 (en) 2001-08-24 2003-03-06 Pharmacia & Upjohn Company Substituted-heteroaryl-7-aza[2.2.1]bicycloheptanes for the treatment of disease
JP2005527472A (ja) * 2001-09-12 2005-09-15 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 疾患治療のための置換された７−アザ［２．２．１］ビシクロヘプタン
NZ531786A (en) 2001-10-02 2006-10-27 Upjohn Co Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
EP1453828A2 (en) * 2001-10-16 2004-09-08 AstraZeneca AB Azabicyclic compounds for the treatment of fibromyalgia syndrome
BR0213760A (pt) * 2001-10-26 2004-10-19 Upjohn Co Composto, composição farmacêutica, uso do composto e método para tratamento de doença ou condição
US6849620B2 (en) 2001-10-26 2005-02-01 Pfizer Inc N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
CA2466375A1 (en) * 2001-11-08 2003-05-15 Pharmacia & Upjohn Company Azabicyclic-substituted-heteroaryl compounds for the treatment of disease
WO2003042210A1 (en) 2001-11-09 2003-05-22 Pharmacia & Upjohn Company Azabicyclic-phenyl-fused-heterocyclic compounds and their use as alpha7 nachr ligands
DE10156719A1 (de) 2001-11-19 2003-05-28 Bayer Ag Heteroarylcarbonsäureamide
DE10162375A1 (de) * 2001-12-19 2003-07-10 Bayer Ag Bicyclische N-Aryl-amide
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
JP2005522456A (ja) 2002-02-15 2005-07-28 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー Ｃｎｓ関連障害治療のためのアザビシクロ置換ベンゾイルアミドおよびチオアミド
CA2476681A1 (en) * 2002-02-19 2003-08-28 Bruce N. Rogers Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease
EP1476448A2 (en) 2002-02-19 2004-11-17 PHARMACIA & UPJOHN COMPANY Azabicyclic compounds for the treatment of disease
DE10211416A1 (de) * 2002-03-15 2003-09-25 Bayer Ag Essig- und Propionsäureamide
DE10211415A1 (de) * 2002-03-15 2003-09-25 Bayer Ag Bicyclische N-Biarylamide
US7977485B2 (en) * 2002-06-10 2011-07-12 Bayer Schering Pharma Aktiengesellshaft 2-heteroaryl carboxamides
EP1542999A1 (en) 2002-08-01 2005-06-22 Pharmacia & Upjohn Company LLC 1h-pyrazole and 1h-pyrrole-azabicyclic compounds with alfa-7 nachr activity
GB0220581D0 (en) * 2002-09-04 2002-10-09 Novartis Ag Organic Compound
BR0317110A (pt) * 2002-12-11 2005-10-25 Pharmacia & Upjohn Co Llc Tratamento de doenças com combinações de agonistas do receptor nicotìnico da acetilcolina alfa 7 e outros compostos
AU2004206107A1 (en) * 2003-01-22 2004-08-05 Pharmacia & Upjohn Company Llc Treatment of diseases with alpha-7 nach receptor full agonists
GB0310867D0 (en) * 2003-05-12 2003-06-18 Novartis Ag Organic compounds
WO2005000250A2 (en) * 2003-06-24 2005-01-06 Johns Hopkins University Imaging agents and methods of imaging alpha 7-nicotinic cholinergic receptor
DE10334724A1 (de) * 2003-07-30 2005-02-24 Bayer Healthcare Ag N-Biarylamide
BRPI0417927A (pt) * 2003-12-22 2007-04-17 Astrazeneca Ab composto, métodos para o tramento ou a profilaxia de uma doença ou condição, e de distúrbios, e para a indução da cessação do hábito de fumar, composição farmacêutica, e, uso de um composto
AU2004303740A1 (en) * 2003-12-22 2005-07-07 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
PE20060437A1 (es) 2004-06-18 2006-06-08 Novartis Ag COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
GB0424564D0 (en) 2004-11-05 2004-12-08 Novartis Ag Organic compounds
CN101213182A (zh) * 2005-06-29 2008-07-02 阿斯利康(瑞典)有限公司 作为α7烟碱性受体调节剂的噻吩-2-甲酰胺
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
EP2520561B1 (en) 2007-06-08 2016-02-10 MannKind Corporation IRE-1A Inhibitors
WO2009013535A1 (en) * 2007-07-23 2009-01-29 Astrazeneca Ab 2-azabicyclo(2.2.2)octane derivatives as modulators of the glycine transporter i receptor
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
JP2013507417A (ja) 2009-10-13 2013-03-04 エム・エス・ディー・オス・ベー・フェー アセチルコリン受容体に関連する疾患の処置のための縮合アジン誘導体
SA111320455B1 (ar) 2010-05-17 2014-10-16 Envivo Pharmaceuticals Inc صورة بلورية من (R)-7- كلورو -N- (كينوكليدين -3- يل) بنزو[b] ثيوفين -2- كربوكساميد هيدروكلوريد أحادي الهيدرات
KR101928505B1 (ko) * 2011-01-28 2018-12-12 에스케이바이오팜 주식회사 피리돈 유도체 및 이를 포함하는 약학적 조성물
KR101925971B1 (ko) * 2011-01-28 2018-12-06 에스케이바이오팜 주식회사 피리돈 유도체 및 이를 포함하는 약학적 조성물
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
WO2013010679A1 (en) 2011-07-15 2013-01-24 Novartis Ag Salts of aza-bicyclic di-aryl ethers and methods to make them or their precursors
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
EP3666272A1 (en) 2012-05-08 2020-06-17 Forum Pharmaceuticals Inc. Use of encenicline in the treatment of cognitive impairment, alzheimer's disease, memory deficit
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
US9593106B2 (en) 2013-02-07 2017-03-14 Heptares Therapeutics Limited Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic M4 receptor agonists
CN105324372B (zh) 2013-06-21 2018-03-06 武田药品工业株式会社 作为前动力蛋白受体调节剂的1‑磺酰基哌啶衍生物
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
GB201318222D0 (en) 2013-10-15 2013-11-27 Takeda Pharmaceutical Novel compounds
GB201320905D0 (en) 2013-11-27 2014-01-08 Takeda Pharmaceutical Therapeutic compounds
FI20145054L (fi) * 2014-01-21 2015-07-22 Tellabs Oy Tiedonsiirtoverkon verkkoelementti
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
KR101623138B1 (ko) 2014-10-28 2016-05-20 한국원자력연구원 베타 아밀로이드 플라크 검출 및 알츠하이머 질환 진단 또는 치료용 조성물
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
GB201619514D0 (en) 2016-11-18 2017-01-04 Takeda Pharmaceuticals Co Novel compounds
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1416872A (en) * 1972-03-10 1975-12-10 Wyeth John & Brother Ltd 4-aminoquinoline derivatives
FI791491A (fi) * 1979-05-10 1980-11-11 Kopo Konepohja Oy Traebitshugg
FR2529548A1 (fr) 1982-07-02 1984-01-06 Delalande Sa Nouveaux derives de l'amino-3 quinuclidine, leur procede et leur application en therapeutique
US4605652A (en) * 1985-02-04 1986-08-12 A. H. Robins Company, Inc. Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes
US4863919A (en) * 1988-02-01 1989-09-05 A. H. Robins Company, Incorporated Method of enhancing memory or correcting memory deficiency with arylamido(and arylthiomido)-azabicycloalkanes
EP0546181B1 (en) * 1990-08-31 1995-08-02 Nippon Shinyaku Company, Limited Indole derivatives and their use as serotonin antagonists
JPH04247081A (ja) * 1991-02-01 1992-09-03 Takeda Chem Ind Ltd ５員複素環酸アミド類
SE9904176D0 (sv) 1999-11-18 1999-11-18 Astra Ab New use
SE0000540D0 (sv) * 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
FR2809730B1 (fr) 2000-05-31 2002-07-19 Sanofi Synthelabo Derives de 1,4-diazabicyclo[3.2.2] nonanebenzoxazole, -benzothiazole et -benzimidazole, leur preparation et leur application therapeutique
FR2809732B1 (fr) 2000-05-31 2002-07-19 Sanofi Synthelabo DERIVES DE 4(-2-PHENYLTHIAZOL-5-yl)-1,4-DIAZABICYCLO-[3.2.2] NONANE, LEUR PREPARATION ET LEUR APPLICATION ENTHERAPEUTIQUE
FR2809731B1 (fr) 2000-05-31 2002-07-19 Sanofi Synthelabo Derives de 1,4-diazabicyclo-[3.2.2] nonane-pheylisoxazole, leur preparation et leur application en therapeutique
TW593223B (en) 2000-06-20 2004-06-21 Merz Pharma Gmbh & Co Kgaa 1-amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists
AU2001284645A1 (en) 2000-08-18 2002-03-04 Pharmacia And Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
WO2002016357A2 (en) 2000-08-18 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
EP1381603A2 (en) 2000-08-18 2004-01-21 PHARMACIA & UPJOHN COMPANY Quinuclidine-substituedaryl moieties for treatment of disease ( nicotinic acetylcholine receptor ligands )
US6492385B2 (en) * 2000-08-18 2002-12-10 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
WO2002016355A2 (en) 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic) acetylcholine receptor ligands
WO2002017358A2 (en) 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists)
AU2001284646A1 (en) 2000-08-21 2002-03-04 Pharmacia And Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
DE10045112A1 (de) 2000-09-11 2002-03-21 Merck Patent Gmbh Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems
AU2002220517A1 (en) 2000-12-01 2002-06-11 Neurosearch A/S 3-substituted quinuclidines and their use as nicotinic agonists
US20020086871A1 (en) 2000-12-29 2002-07-04 O'neill Brian Thomas Pharmaceutical composition for the treatment of CNS and other disorders
AU2004303740A1 (en) * 2003-12-22 2005-07-07 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
US7396830B2 (en) * 2005-10-04 2008-07-08 Bristol-Myers Squibb Company Piperazine amidines as antiviral agents

Also Published As

Publication number Publication date
NO20023917L (no) 2002-09-16
DK1259508T3 (da) 2004-02-16
US7001914B2 (en) 2006-02-21
NZ520094A (en) 2005-01-28
IL150544A0 (en) 2003-02-12
BG106977A (bg) 2003-05-30
CZ20022787A3 (cs) 2003-02-12
ES2208556T3 (es) 2004-06-16
EP1259508A1 (en) 2002-11-27
ATE252099T1 (de) 2003-11-15
PL202044B1 (pl) 2009-05-29
IS6492A (is) 2002-08-08
WO2001060821A1 (en) 2001-08-23
MY123580A (en) 2006-06-30
CN100345847C (zh) 2007-10-31
KR20020072585A (ko) 2002-09-16
ZA200205479B (en) 2003-12-31
EE200200459A (et) 2003-12-15
DE60100996T2 (de) 2004-09-02
HUP0301069A3 (en) 2004-09-28
TR200400072T4 (tr) 2004-02-23
DE60100996D1 (de) 2003-11-20
PT1259508E (pt) 2004-03-31
US7214688B2 (en) 2007-05-08
HUP0301069A2 (hu) 2003-08-28
CA2397233A1 (en) 2001-08-23
SK11792002A3 (sk) 2003-04-01
CN1400973A (zh) 2003-03-05
EP1259508B1 (en) 2003-10-15
US20060128749A1 (en) 2006-06-15
JP2003523342A (ja) 2003-08-05
US20030008867A1 (en) 2003-01-09
US20070149563A1 (en) 2007-06-28
RU2263114C2 (ru) 2005-10-27
HK1050007A1 (en) 2003-06-06
AU782693B2 (en) 2005-08-18
AR029798A1 (es) 2003-07-16
CO5280046A1 (es) 2003-05-30
JP4084570B2 (ja) 2008-04-30
NO20023917D0 (no) 2002-08-16
PL357565A1 (en) 2004-07-26
AU3259401A (en) 2001-08-27
EE05149B1 (et) 2009-04-15
US7491734B2 (en) 2009-02-17
KR100769394B1 (ko) 2007-10-22
MXPA02007543A (es) 2002-12-13
UA73540C2 (en) 2005-08-15
BR0108456A (pt) 2003-04-01

Similar Documents

Publication Publication Date Title
SE0000540D0 (sv) New compounds
CY1107634T1 (el) Φαρμακευτικη συνθεση
DOP2001000151A (es) Derivados de imidazopirimidina y derivados de triazolopimidina.
DE60135919D1 (de) Farnesyl transferase-hemmende 6-heterocyclylmethyl-chinolin und chinazol-derivate
CY1106132T1 (el) Παραγωγα πιπepιδινης ως αναστολεις καναλιου καλιου
DE60335359D1 (de) Phthalazinonderivate
NO20031001L (no) Polyarylkarboksamider nyttige som lipidsenkende midler
CY1106247T1 (el) Θειοφαινο- και θειαζολοσουλφοναμιδες ως αντινεοπλαστικοι παραγοντες
CY1113648T1 (el) Παραγωγα πυριδινονης για θεραπεια αθηροσκληρωσης
CY1108738T1 (el) Θεραπευτικοι παραγοντες χρησιμοι για την αγωγη του πονου
CY1113657T1 (el) Νεα παραγωγα βενζοφαινονης ή αλατα αυτων
PT1193270E (pt) Pirrolobenzodiazepinas
EE200300088A (et) Imidasolo-5-üül-2-anilino-pürimidiinid raku proliferatsiooni inhibitsiooni agensitena
BR0214268A (pt) Aperfeiçoamentos em relação a abrilhantadores ópticos
PT1181294E (pt) Novos derivados e analogos da galantamina
DE69812634D1 (de) Metalloproteinase-inhibitoren
ATE411287T1 (de) Neue metallproteinaseinhibitoren
SE9901077D0 (sv) Novel use
ATE333457T1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
SV2003000981A (es) Fenil-heterociclil-eteres ref. pcs10973
BRPI0416678A (pt) pirazolpirimidinas
MY128164A (en) Compounds
DE60041001D1 (de) Substituierte homopiperidylbenzimidazolanaloga als fundusrelaxantien
EE200200389A (et) Imidasooli uued derivaadid
EA200600608A1 (ru) Производные имидазопиридина как ингибиторы индуцируемой no-синтазы